Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMQB4VN)

Drug Name

MGD006 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Phase 1	[1]
Acute myeloid lymphoma	2A80	Phase 1	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 3 receptor alpha (IL3RA)	TTENHJ0	IL3RA_HUMAN	Modulator	[2]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Modulator	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Interleukin 3 receptor alpha (IL3RA)	DTT	IL3RA	1.807	3.926	2.678	3.573

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Acute lymphoblastic leukaemia

ICD Disease Classification

2A85

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin 3 receptor alpha (IL3RA)	DTT	IL3RA	8.71E-54	0.98	2.64

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87.
2	A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.Sci Transl Med.2015 May 27;7(289):289ra82.